BridgeBio Pharma (BBIO) said Monday that the UK's Medicines and Healthcare Products Regulatory Agency granted marketing authorization for its drug, acoramidis, branded as Beyonttra, for treating transthyretin amyloidosis in adults with cardiomyopathy, including both wild-type and variant forms of the disease.
The company said the approval was based on a phase 3 trial result, where acoramidis significantly reduced cardiovascular hospitalizations, improved survival and preserved patients' physical function and quality of life over 30 months.
Under a partnership formed in 2024, the company said Bayer would handle all UK commercial activities for the drug, and it would receive tiered royalties starting in the low 30% range.
Beyonttra has already been approved in the US, EU, and Japan.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。